Overview

Semaglutide vs Sitagliptin

Status:
Not yet recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

The effect of once daily dosing of oral Semaglutide versus once daily dosing Sitagliptin on glycemic control, body weight, and safety and tolerability will be compared in Liver Transplant Recipients with poorly-controlled Diabetes Mellitus.

Phase:

Phase 4

Details

Lead Sponsor:

University Health Network, Toronto

Collaborator:

Novo Nordisk A/S

Treatments:

Sitagliptin Phosphate